EB-1020 (Centanafadine) 164.4 mg Clinical Trials
2 recruitingDrug
Phase 32Phase 21
Showing 1–2 of 2 trials
Recruiting
Phase 2Phase 3
Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
Attention Deficit Hyperactivity Disorder (ADHD)
Otsuka Pharmaceutical Co., Ltd.630 enrolled1 locationNCT06931080
Recruiting
Phase 3
A Long-term Trial of EB-1020 in Adult Patients With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
Otsuka Pharmaceutical Co., Ltd.180 enrolled1 locationNCT06926829